Prior to the advent of EGFR-tyrosine kinase inhibitors (TKIs), platinum-based chemotherapy (PBC) was the standard first-line (1L) treatment for EGFRm advanced NSCLC, with modest treatment outcomes.7 Here, EGFR is linked to non-small cell lung carcinoma.